Literature DB >> 28974585

Routine screening in the general hospital: what happens after discharge to those identified as at risk of dementia?

Ana Phelps1, Bethany Kingston2, Rose M Wharton3, Sarah T Pendlebury4.   

Abstract

Cognitive screening is recommended for older patients with unplanned hospital admission. We determined rates of reassessment/specialist memory referral after routine inclusion of at risk of dementia status in discharge documentation to primary care. Questionnaires were sent to relevant GP practices on consecutive patients aged ≥75 years identified as at risk and discharged 6 months earlier. Among 53 patients (mean age ±SD = 87.3±6.0 years, mean±SD Abbreviated Mental Test Score = 4.4±2.7), 49 (92%) patients had been reviewed since discharge, and 12/43 (28%) without previously known cognitive problem had had a cognitive reassessment. The most common reasons for non-assessment/referral included clinical factors (eg terminal illness/comorbidities) (n=15) and patient/family wishes (n=5) and that confusion was expected in unwell older patients (n=5). Routine cognitive reassessment/specialist referral appears unjustified in patients identified as at risk of dementia during unplanned hospital admission. However, the prognostic value of delirium/confusion in acute illness is under-recognised and could be used to highlight those at risk. © Royal College of Physicians 2017. All rights reserved.

Entities:  

Keywords:  at-risk; dementia; hospitalisation; primary care; prognosis

Mesh:

Year:  2017        PMID: 28974585      PMCID: PMC6301921          DOI: 10.7861/clinmedicine.17-5-395

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  1 in total

1.  Impact of a system-wide multicomponent intervention on administrative diagnostic coding for delirium and other cognitive frailty syndromes: observational prospective study.

Authors:  Sarah T Pendlebury; Nicola G Lovett; Ross J Thomson; Sarah C Smith
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.